







































Does a screening trial for spinal cord stimulation in
patients with chronic pain of neuropathic origin
have clinical utility and cost-effectiveness (TRIAL-
STIM)? A randomised controlled trial
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Abstract
Spinal cord stimulation (SCS) is an established treatment of chronic neuropathic pain. Although a temporary SCS screening trial is
widely used to determine whether a patient should receive permanent SCS implant, its evidence base is limited. We aimed to
establish the clinical utility, diagnostic accuracy, and cost-effectiveness of an SCS screening trial. A multicentre single-blind, parallel
two-group randomised controlled superiority trial was undertaken at 3 centres in the United Kingdom. Patients were randomised 1:1
to either SCS screening trial strategy (TG) or no trial screening strategy (NTG). Treatment was open label, but outcome assessors
were masked. The primary outcomemeasure was numerical rating scale (NRS) pain at 6-month follow-up. Between June 2017 and
September 2018, 105 participants were enrolled and randomised (TG 5 54, NTG 5 51). Mean numerical rating scale pain
decreased from 7.47 at baseline (before SCS implantation) to 4.28 at 6 months in TG and from 7.54 to 4.49 in NTG (mean group
difference: 0.2, 95% confidence interval [CI]:21.2 to 0.9, P5 0.89). We found no difference between TG and NTG in the proportion
of pain responders or other secondary outcomes. Spinal cord stimulation screening trial had a sensitivity of 100% (95% CI: 78-100)
and specificity of 8% (95% CI: 1-25). The mean incremental cost-effectiveness ratio of TG vs NTG was £78,895 per additional
quality-adjusted life-year gained. In conclusion, although the SCS screening trial may have some diagnostic utility, there was no
evidence that an SCS screening TG provides superior patient outcomes or is cost-effective compared to a no trial screening
approach.
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1. Introduction
Neuropathic pain is a complex and heterogeneous disorder that
affects up to 8% of the adult population3 with substantial impact
on health-related quality-of-life (HRQoL).42,43 Despite the avail-
ability of numerous pharmacological options, up to 50% of
patients with neuropathic pain fail to obtain pain relief from pain
relieving medication.17
Spinal cord stimulation (SCS) is an effective treatment for
severe neuropathic pain.32 In Europe, North America, and many
other countries, clinical guidelines and healthcare payers typically
require patients to undergo a successful SCS screening trial to be
able to receive an SCS implant.4,5,11,32 The approach to SCS
screening trials varies between countries and clinical centres from
a test stimulation of a fewminutes immediately before permanent
SCS implantation44 to a test period as long as 28 days.4 The
primary aim of a screening trial is to allow the patient to test the
efficacy of the SCS. An expert clinical panel has defined a
successful trial as the patient reporting $50% pain relief with
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stable or reduced pain medications and with stable levels of daily
activity.11
A screening trial seems to be a low burden (“try before you
buy”) intervention because it allows patients to experience the
sensation generated by SCS and its interaction with body
movements, determine the appropriate lead location, and to
formulate a broad evaluation of the pain relief; and provides
physicians with an estimate of electrical current consumption
required from the device that guides their choice of a relatively
expensive SCS implantable pulse generator and choice between
paddle lead or percutaneous leads. However, SCS screening
trials are not without their drawbacks: they require a duplication of
a clinical procedure, and they expose patients to a higher risk of
infection (due to bacterial colonisation of the lead skin exit site);
indeed, 28-day trials have been associated with higher infection
rates when compared with shorter trial durations.34,36 Screening
trials using permanent anchored lead have resulted in an
increasing number of wound infections (6.52%) and poor wound
healing (4.35%) when compared to percutaneous temporary lead
trials (1.35% and 0%, respectively).38 Furthermore, SCS trials can
be associated with moderate surgical pain up to 6 days after the
procedure calling into question a patient’s ability to judge the
impact of SCS on their original pain.6 Percutaneous insertion of
SCS leads have on occasion resulted in epidural and intracranial
bleeding and even death.1,39
In summary, although SCS screening trials are used worldwide
as part of routine clinical practice to assess whether an SCS
device should be made available to patients, there is limited
evidence for their use and they may have limited clinical value,
increased patient risk, and higher healthcare costs. We present
the first randomised controlled trial (RCT) designed to determine
the clinical utility and cost-effectiveness of an SCS screening trial.
We hypothesised that a no SCS screening trial strategy (TG) will
be superior to an SCS screening trial and more cost-effective for
patients with chronic neuropathic pain.
2. Methods
2.1. Study design and participants
TRIAL-STIM was a multicentre, single-blind, parallel 2-group
randomised trial with an economic evaluation (ISRCTN,
ISRCTN60778781). Our full study protocol has been published
elsewhere.15
Patients were recruited from the outpatient clinics of 3
participating sites in the United Kingdom: South Tees Hospitals
NHS Foundation Trust (The James Cook University Hospital),
Basildon and Thurrock University Hospitals NHS Foundation
Trust, and Leeds Teaching Hospitals NHS Trust. Inclusion criteria
were adults ($18 years) who are clinically considered to be
candidates for SCS in accord with current NHS guidance (NICE
TA159)32; pain of neuropathic nature of an intensity of at least 5 as
assessed on a numerical rating scale (NRS); persistent pain for
more than six months despite appropriate conventional medical
and surgical management including transcutaneous electric
nerve stimulation (TENS), acupuncture, oral analgesic agents,
cognitive behavioural therapy as well as nerve blockade where
appropriate; satisfactory multidisciplinary assessment by a team
with expertise in delivering SCS therapy; and capacity to provide
informed consent. Exclusion criteria were: the presence of an
ongoing pain condition considered by the investigator to
overshadow the neuropathic pain condition to be treated with
SCS; current or previous treatment with an implanted pain relief
device; current participation or planned participation in other
studies that may confound the results of this study; ongoing
anticoagulation therapy, which cannot be safely discontinued;
poor cognitive ability or lack of capacity; unable to undergo study
assessments or complete questionnaires independently; and
patient was pregnant or planning to become pregnant during the
course of the study.
Patients who were scheduled to have an SCS trial were
approached and given a Patient Information Sheet to take home
to read. Informed consent was obtained from suitable patients
after a reasonable period by one of the principal investigators or
delegated individuals at each site following International Confer-
ence on Harmonisation/Good Clinical Practice (ICH/GCP)
guidelines.33
The study was approved by the United Kingdom Health
Research Authority North East Research Ethics Committee (17/
NE/0056). The trial was conducted and reported in accordance
with CONSORT guidelines.37
2.2. Randomisation and masking
Participants were allocated in a 1:1 ratio to 1 of the 2 groups:
either a strategy of a screening trial followed by SCS implantation
based on the screening trial result (TG) or a no trial screening SCS
implantation only strategy (NTG). Patients were randomly
assigned to groups by means of a password-protected web-
based system developed and maintained by Exeter Clinical Trials
Unit (ExeCTU). Allocation was stratified by centre and minimised
on patient age ($65 or, 65 years), sex, and presence of FBSS.
Once the patient completed the screening interview and baseline
data collection interview, the researcher accessed the random-
isation website using a unique username and password.
Treatment allocation was concealed from the patients, investi-
gator, and site staff.
It is not possible to blind patients, clinicians, or all of the
research team to group allocation. However, to minimise
assessment bias, we sought to blind researchers undertaking
outcome assessment and data analysts to group allocation by
masking them from group allocation. Each site team consisted of
blinded and unblinded assessors. These did not cross roles or
exchange information. Database entries were also clearly divided
into blinded and unblinded sections with no potential for cross-
data entry because blinded assessor login only allowed access to
a limited set of data. Data analysts were masked to group
allocation until the analyses were presented to the Trial Steering
Committee (TSC).
2.3. Procedures
2.3.1. Screening trial and implantation strategy
Patients randomised to this arm received a screening trial
consisting of passage of either an external or internalised
tunnelled SCS lead or leads attached to an external stimulator
as per centre’s routine practice. Taking into consideration the
RCTs25,26 included in the clinical evidence section of NICE
TA15932 as well as international guidelines,11 a successful
screening trial was defined as $50% pain relief and satisfactory
on-table paraesthesia coverage (ie, $80%) of the pain area,
reduction in pain medications or improved quality of life and
function, and successful location of leads at anatomical target for
paraesthesia-free therapies. Patients with an unsuccessful
screening trial were not implanted but all patients were to be
followed-up to six months. Successful trial patients had the
implantable pulse generator implanted on a separate occasion.
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2.3.2. Implantation only strategy (NTG)
In the implantation only strategy group, all patients with
satisfactory on-table paraesthesia coverage (ie, $80%) of the
pain area, no dislike of sensations,16 and satisfactory anatomical
lead location for paraesthesia-free devices received a permanent
implant in one surgery.
2.4. Outcomes
The primary outcome measure was the pain NRS at 6-month
follow-up.14 Secondary outcome measures included mean pain
intensity measured on the NRS over 4 days, the proportion of
patients achieving at least 50% and 30% pain relief at six months
as measured on the NRS,14 HRQoL (EQ-5D-5L),21 function
(Oswestry Disability Index),18 patient satisfaction (Patients’ Global
Impression of Change),20 and complication rates.
Diagnostic performance of the SCS trial stimulation was
reported as sensitivity, specificity, positive, and negative pre-
dictive values, and positive and negative likelihood ratios.
The economic analysis (appendix pp 6-16) was conducted
fromanNHSperspective with additional analyses presented from
a societal perspective to include productivity losses. For each
patient enrolled in the trial, clinical data and resource events at
specificmeasurement points including the day of the intervention,
as well as 3- and 6-month follow-up were registered in the case
report form.28 These included appointments with healthcare
professionals, procedures performed, investigations, inpatient
hospitalisations, treatment given, management of adverse
events, and work absenteeism related with the chronic pain
condition.
All unit costs were for the price year 2017 to 2018. Intervention
costs were taken from standard national costs. Secondary care
data were valued using the National Reference Costs from the
Department of Health.12 Primary and community-based health
services were valued using National Reference Costs from the
Personal Social Services Research Unit.8 Productivity costs were
valued from the patient’s perspective using the human capital
approach. The appendix shows full details of all unit costs.
2.5. Statistical analysis
The study was powered to detect a statistically significant and
clinically meaningful between-group difference using our primary
outcome based on an intention-to-treat analysis. Assuming that
the SCS screening trial has little or no clinical utility, we
hypothesised superiority of the no-screening strategy over the
screening strategy. For a pain NRS (scores 0-10), IMMPACT
proposes a minimal clinically important difference of 2 points.14
Based on a typical pain NRS SD of 2.5 seen in previous SCS
RCTs, at 90% power, 5% alpha, and a worst-case attrition rate of
30%, we required a total of 50 patients recruited per group.
A sample size of 50 patients in the TG arm determined our
precision to estimate the specificity and sensitivity of the SCS
screening test. Given the lack of previously published sensitivity
and specificity values for the SCS screening test, Table 1 presents
the margins of error of estimation (width of the 95% confidence
interval [CI]) based on 50 patients in the implantation strategy arm
across a range of possible values of diagnostic performance.
2.6. Comparison of effectiveness
Analyses were conducted and reported in accord with CONSORT
recommendations.37 Primary analysis was conducted on an
intention-to-treat basis (ie, according to randomised group allocation)
and compared primary and secondary outcomes at 6-month follow-
up between randomised groups with complete data sets. Continu-
ous outcomes were compared using linear regression methods
adjusting for baseline outcome scores and stratification/minimisation
variables. Binary outcomes were compared using logistic regression
analysis with adjustment for stratification/minimisation variables and
site. A number of secondary analyses were undertaken: (1)
comparison of primary and secondary outcomes at 3 months in
patients with complete data; (2) comparison of primary and
secondary outcomes at 3- and 6-month follow-up using different
methods of imputation that included multiple imputation, last
observation carried forward (LOCF), worst case scenario (LOCF
and then reduce outcomes by the minimum important difference, ie,
NRS add 2.0, EQ-5D subtract 0.1, Oswestry Disability Index (ODI)
add 5.0; Patient Global Impression of Change if missing assume
dissatisfied), and best case scenario (LOCF and then increase
outcomes by minimum important difference, ie, NRS subtract 2.0,
EQ-5D add 0.1, ODI subtract 5.0, Patient Global Impression of
Change if missing assume satisfied); and (3) exploratory subgroup
analyses using interaction terms for stratification and minimisation
variables and type of stimulation (conventional, high-frequency, burst)
for primary outcome.
2.7. Diagnostic performance
Analyses were conducted and reported in accord with Standards
for Reporting of Diagnostic Accuracy Studies (STARD) recom-
mendations.2 Cross-tabulation was used to report the SCS
screening trial results (fail vs success) vs SCS pain relief ($50%
vs ,50%) at 3- and 6-month follow-up. Positive and negative
predictive value and likelihood ratios are also reported. Given the
loss of follow-up of negative trial screens, post hoc best and worst
case sensitivity analyses were undertaken—base case: assume
missing screen negatives are true negatives (ie, have ,50% pain
relief at follow-up), orworst case: assumemissing screennegatives
are false negatives (ie, have$50% pain relief at follow-up).
2.8. Economic analysis
Analyses were conducted and reported in accord with Consol-
idated Health Economic Evaluation Reporting Standards
(CHEERS) recommendations.23 Differences in costs and utilities
between the groups were compared using linear regression
methods adjusting for baseline EQ-5D-5L index scores and
stratification/minimisation variables. The base case economic
analysis compared TG vs NTG from an NHS perspective, with
additional analysis presented to include productivity losses. A
cost-utility analysis was conducted and the incremental cost-
effectiveness ratio (ICER) reported. This was done by calculating
the ratio of the difference in mean costs and mean change in
quality adjusted life years (QALY) in terms of HRQoL gained.
Table 1
Margins of error of estimation.





* Assuming 40/50 patients have $50% pain relief at 6 months.
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Uncertainty around the cost and effectiveness estimates was
represented by cost-effectiveness acceptability curves.
All analyseswere prespecified in a detailed statistical analysis plan
and a health economic analysis plan that were reviewed by the
independent TSC.All analyseswereundertakenusingSTATAv16.0.
3. Results
Of 137 patients assessed between June 2017 and September
2018, 105 (63%) were eligible to participate. The primary reason for
exclusion was declining to participate (Fig. 1). Of the 105
participants, 54 were randomly allocated to the trial screening
strategy group (TG). Seven TG patients withdrew before trial screen;
of the remaining 47, 5 (11%) had an unsuccessful trial screen and 42
(89%) had a successful trial screen andwere implantedwith an SCS
system. The mean screening trial duration was 9.3 days (SD 5 4;
median 5 7; range 5-22). Thirty-three (70%) of the screening trials
were definitive trials (ie, permanent anchored lead) and 14 (30%)
were external lead trials (ie, percutaneous temporary lead). Of the 51
NTG patients, 49 received an SCS implant.
Study participants had an average age of 50.4 years and relatively
equal representation by sex, with a mean NRS pain of 7.5 and
primarily a failed back surgery syndrome diagnosis (53%) (Table 2).
Thebaseline characteristics andoutcomescores of the TGandNTG
groups were relatively well balanced, the only exception being the
duration of pain that was somewhat longer in the NTG group.
Primary outcome data were available for 85 (81%) patients at 3
months (37 TG and 48 NTG) and 89 (85%) patients (41 TG and 48
NTG) at 6months. Therewas no evidence of difference in the age,
sex distribution, duration of pain, or baseline outcome score of
patients who were lost to follow-up at either 3 or 6 months
compared to those with data.
There was no difference in the primary outcome of clinic-
assessed NRS score between TG and NTG at 6-month follow-up
Figure 1. Trial profile.
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(mean difference: 0.2, 95% CI: 21.2 to 0.9, P 5 0.74) (Table 3).
There was evidence of substantial reduction inmean NRS pain from
baseline to 6 months for both TG (7.5-4.3) and NTG (7.5-4.5). No
between-group difference at 6 months was seen for the secondary
outcomes of 4-day diary NRS, EQ-5D-5L, ODI, PGIC, and 30%and
50% pain reduction. Improvements were seen in 4-day diary NRS,
EQ-5D-5L, and ODI from baseline to 6-months in both groups. A
similar pattern of primary and secondary outcome results was seen
at 3 months with exception of 30% pain relief that was higher for TG
(74%) than NTG (48%) (Appendix, supplementary table 1, available
at http://links.lww.com/PAIN/B94).
The finding of no difference between TGandNTGat 6monthswas
robust to various imputation analyses for the handling of missing
outcome (Appendix, supplementary table 2, available at http://links.
lww.com/PAIN/B94). Exploratory interaction analyses showed no
significant subgroup effects for NRSpain at 6-month follow-up by site
(P 5 0.25), sex (P 5 0.17), age (P 5 0.96), failed back surgery
syndrome or not (P 5 0.85), and type of stimulation (P 5 0.70)
(Appendix, supplementary table 3, available at http://links.lww.com/
PAIN/B94).Our analysis of concomitant analgesia foundnodifference
between groups that could account for our findings (Appendix,
supplementary table 4, available at http://links.lww.com/PAIN/B94).
Diagnostic performance results of the trial screen at 3- and 6-
month follow-up are reported in Table 4. All patients who
reported $50% pain relief at 6-month follow-up had a positive
trial screen (ie, $50% pain relief) and therefore a sensitivity of
100%. Of the 26 participants who reported ,50% pain relief at
6months, 2 had negative screening trials, that is, specificity of 8%.
Of the 5 participants who had a negative screening trial (ie,
,50%pain relief) (Fig. 1), data were only available at 6months for
2 participants who both reported ,50% pain relief. If it was
assumed that all 3 patients with a negative test who dropped out
had $50% pain relief at 6 months; this would give a sensitivity of
83% and specificity of 8% (see Appendix, supplementary table 5,
available at http://links.lww.com/PAIN/B94). Alternatively, if it
was assumed that they had ,50% pain relief at 6 months, this
would give a sensitivity of 100% and specificity of 17% (see
Appendix, supplementary table 6, available at http://links.lww.
com/PAIN/B94). A similar pattern of results was seen at 3-month
follow-up.
A screening trial was estimated to cost £19,073.38 per
participant in TG, with an implant only strategy estimated to
cost £17,487.90 per participant in NTG (mean difference
£1341.22 (95% CI 234.26 to 2832.85). Results including
Table 2
Baseline characteristics and outcome scores.
TG (n 5 54) NTG (n 5 51) Both groups (n 5 105)
Age, mean (SD) 49.4 (12.6) 51.5 (10.9) 50.4 (12.0)
Gender, male n (%) 22 (41) 22 (43) 44 (42)
Cause of pain, n (%) (primary diagnosis)
CRPS type I 8 (15) 1 (2) 9 (9)
CRPS type II 1 (2) 2 (4) 3 (3)
Radiculopathy 8 (15) 12 (23) 20 (19)
Arachnoiditis 1 (2) 0 (0) 1 (1)
Chronic postsurgery pain 6 (11) 2 (4) 8 (8)
Neuropathic low back pain 5 (9) 4 (8) 9 (9)
FBSS 28 (52) 28 (55) 56 (53)
Other 9 (17) 13 (25) 22 (21)
Duration of pain (mo), mean (SD) 108 (98) 128 (100) 117 (99)
Previous surgery relevant to the pain, n (%) (Pain
Aetiology classification)
Surgery 24 (44) 25 (49) 49 (47)
Medical condition 15 (28) 17 (33) 32 (31)
Road traffic accident 3 (6) 3 (6) 6 (6)
Other—trauma, accident (work related/falls
etc)
15 (28) 9 (18) 24 (23)
Other 3 (6) 5 (10) 8 (8)
Pain medication intake, n (%)
Analgesics 53 (98) 50 (98) 103 (98)
Antidepressants (tricyclics/tetracyclics/SSRIs) 47 (87) 45 (88) 92 (88)
Anticonvulsants 40 (74) 38 (74) 78 (74)
Muscle relaxants 17 (31) 23 (45) 40 (38)
NSAIDs 44 (81) 39 (76) 83 (79)
Opioids (transdermal/oral etc) 48 (89) 45 (88) 93 (89)
Sedatives 6 (11) 8 (16) 14 (13)
Steroids 6 (11) 8 (16) 14 (13)
Transdermal anaesthetics 12 (22) 8 (16) 20 (19)
Others 6 (11) 3 (12) 9 (9)
Pain NRS, mean (SD) 7.5 (1.1) 7.5 (1.1) 7.5 (1.1)
ODI, mean (SD) 56.1 (13.6) 57.6 (14.9) 56.9 (14.2)
EQ-5D index, mean (SD) 0.32 (0.22) 0.30 (0.24) 0.31 (0.23)
CRPS, complex regional pain syndrome; FBSS, failed back surgery syndrome; NRS, numerical rating scale; NSAIDs, non-steroidal anti inflammatory drugs; ODI, Oswestry Disability Index; SSRIs, selective serotonin reuptake
inhibitors; TG, trial strategy.
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productivity losses were also nonsignificant (appendix,
supplementary table 16, available at http://links.lww.com/
PAIN/B94). Cost-effectiveness analysis suggests that from an
NHS perspective, the TG strategy generates more QALYs but
at an increased cost, thus producing an ICER of £78,895 per
additional QALY gained when adjusted for baseline EQ-5D-5L
index score and prespecified stratification variables. The
probability of a screening TG being cost-effective at £20,000
or £30,000 per additional QALY gained (ie, the threshold
commonly adopted in decisions made by NICE) is 9.2% and
13.8%, respectively.
Adverse events at 3- and 6-month follow-up are descriptively
reported by TG and NTG (Appendix, supplementary table 7 and
8, available at http://links.lww.com/PAIN/B94). One patient in TG
experienced a serious adverse event related to an infected
haematoma. Eight participants experienced a total of 10 adverse
events in both TG and NTG. However, the NTG experienced less
device-related AE (n 5 2) compared to the TG (n 5 5). In total, 3
participants, all randomised to the TG group, experienced
implant-related wound infections (all received a definitive trial),
of which 2 required SCS explant, and one was treated with
antibiotics. The patients in TG who experienced anchor site pain,
new neurological change, and lead migration requiring reopera-
tion all received an external trial. Moderate to severe pain around
the implant was reported by 2 subjects, one in TG and one
in NTG.
Table 3
Clinical effectiveness—primary complete case analysis of primary and secondary outcomes at 6-month follow-up.
TG (n 5 41) NTG (n 5 48) Between-group difference
Baseline mean (SD) or
n/N
Follow-up mean (SD) or
n/N
Baseline mean (SD) or
n/N
Follow-up mean (SD) or
n/N






7.5 (1.1) 4.3 (2.4) 7.5 (1.1) 4.5 (2.5) 0.2 (21.2 to 0.9) 0.74
Secondary
outcomes
Pain NRS: 4 d 7.3 (1.1) 4.1 (2.4) 7.4 (0.9) 4.8 (2.6) 0.3 (20.8 to 1.4) 0.60
Pain relief
$50%
— 15/41 (37%) — 19/48 (40%) 1.2 (0.4 to 1.7) 0.73
Pain relief
$30%
— 23/41 (56%) — 28/48 (58%) 1.3 (0.5 to 3.2) 0.55
EQ-5D-5L 0.32 (0.22) 0.57 (0.24) 0.30 (0.24) 0.53 (0.27) 20.06 (20.16 to 0.04) 0.23
PGIC — 38/39 (97%) — 41/47 (87%) 0.2 (0.0 to 2.6) 0.20
ODI 56.1 (13.6) 36.2 (18.4) 57.6 (14.9) 41.4 (23.4) 1.7 (25.8 to 9.2) 0.65
NRS, numerical rating scale; ODI, Oswestry Disability Index; PGIC, Patient Global Impression of Change, TG, trial strategy.
Table 4
Diagnostic performance of test screen—observed data.
Pain relief ‡50% Pain relief <50% Totals
Trial screen positive 17 20 37
Trial screen negative 0 0 0
Totals 17 20 37
3-mo follow-up
Sensitivity (%) 100 (95% CI: 80-100)
Specificity (%) 0 (95% CI: 0-17)
Positive likelihood ratio 1.00 (95% CI: 1.00-1.00)
Negative likelihood ratio Not calculable
Positive predictive value (%) 46 (95% CI: 46-46)
Negative predictive value (%) Not calculable
Pain relief ‡50% Pain relief <50% Totals
Trial screen positive 15 24 39
Trial screen negative 0 2 2
Totals 15 26 41
6-mo follow-up
Sensitivity (%) 100 (95% CI: 78-100)
Specificity (%) 8 (95% CI: 1-25)
Positive likelihood ratio 1.08 (95% CI: 0.97-1.21)
Negative likelihood ratio 0.00
Positive predictive value (%) 38 (95% CI: 36-41)
Negative predictive value (%) 100
CI, confidence interval.
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4. Discussion
Our results indicate that although an SCS screening trial may have
some diagnostic utility, it provides no patient outcome benefits
compared to a no screening trial and direct to permanent SCS
implantation strategy. Our economic evaluation also shows that an
SCS trial is not a cost-effective use of healthcare resources.
Before this study, there was a limited evidence base for the use
of SCS screening trials. The success of screening trials (ie,$50%
pain relief) in recent RCTs has ranged from 88%26 to 93%.24
However, the proportion of patients reporting$50% pain relief at
3- or 6-month follow-up ranges only from 48% to 76%.10,24,26
Diagnostic block before radiofrequency denervation can be
considered akin to screening trials before SCS implantation and
its usefulness has also been questioned. One RCT evaluating
diagnostic nerve blocks before proceeding to radiofrequency
denervation found that these increased costs and decreased the
overall success rate.7 Another RCT found that the use of
prognostic genicular nerve block did not improve the rate of
treatment success.29
A retrospective study reporting on outcomes after different
screening trial strategies observed that a percutaneous tempo-
rary lead trial was associated with fewer false positives and
wound-related complications as compared to a permanent
anchored lead trial.38 A retrospective review of 80 patients who
received SCS after an on-table trial reported that at 12-month
follow-up, 40% of the patients no longer required analgesic
medication and for 37% of patients, the pain was manageable
with first-line analgesics.19 A post hoc analysis of the PROMISE
RCT observed that the only significant contributing factor to
infection was trial duration supporting the hypothesis of a
cause–effect relationship between trial duration and the risk of
infection.34
In a study specifically addressing the role of screening trials,
Weinand et al. retrospectively reviewed 54 patients with chronic
low back pain and/or lower-extremity pain, who underwent acute
on-table trial or a prolonged home trial of an average of 5.0
days.44 Similar to our findings, the study reported that acute (on
table) and prolonged SCS screening trials have equivalent
predictive value for long-term pain control using SCS.
In contrast to our reported positive predictive value of 38%
(95% CI: 36-41), Weinand et al. reported positive predictive value
of 82% and 86% for acute and prolonged screening trials,
respectively. The difference is attributable to the higher propor-
tions of long-term responders ($50% pain relief) in the Weinand
study (ie, 31/38 for acute screening and 31/36 for prolonged
screening) in comparison to our relatively low proportion of
responders of 19/48 and 15/41 for NTG and TG, respectively.
This difference in responder rates may reflect the heterogeneous
neuropathic pain population recruited in our study as well as the
retrospective design and single-centre setting of the Weinand
study.
Screening trials have been suggested to exclude good
candidates for SCS. Oakley reported a small case series of 12
patients implanted with SCS despite failing a screening trial.35
Despite an average pain relief of 21% at the end of screening
trials, thesewent on to report an average pain reduction of 44%at
6 months after SCS implant. We note that the study by Oakley
et al. has several limitations including study design, small sample
size, and assessment of pain intensity that was based on
difference between SCS device off vs SCS device on instead of
differences between timepoints. In the current study, we were
unable to explore the number of false negative trial responders
due to clinical reasons as well as funding restrictions.32
In relation to the economic evaluation, Duarte and Thomson
conducted a cost–impact analysis from a United Kingdom NHS
perspective, considering trial to implant rates reported in the
literature.13 They concluded that considerable savings could be
obtained by adopting an implantation only strategy without a
screening trial. They estimated the point at which equivalent costs
would be observed between a trial screening and implantation
only strategies. At a base price of £17,422 per rechargeable SCS
device, this would occur at the point where 20 out of 100 patients
fail a screening trial. Our findings support those of Duarte and
Thomson. Indeed, we found the total cost to be greater in TG (ie,
screening trial) at £19,073 compared toNTG (no screening trial) at
£17,488. The ICER adjusted for stratification variables was
£78,895 per additional QALY gained. The probability of a
screening trial being cost-effective at a threshold of £30,000
per QALY is only 13.8%. Therefore, the limited patient benefit
obtained by the use of screening trials results in a significantly
higher cost to the health service. Such costs may only be
mitigated in settings where trial failure rates are considerably
higher than those observed in this study, which reflects European
guidance, procedure, and SCS trial success rates. An implant
rate of 91.6% had previously been reported for one of the sites in
this study,41 and the implant rate of 88% observed in the
PROCESS RCT included 2 of the 3 participating sites in the
current RCT.26 In contrast, U.S. trial success rates reportedly
range from as low as 41.4%,22 up to 64.7%.31 The difference
between U.S. and European trial success rates may relate to the
more ready access to psychological evaluation in Europe or to a
difference in the medical indications of the population being
tested or the difference in healthcare setting and payer (eg,
reimbursement not dependent on outcome), physician, and
patient expectations. However, trial success rates reported in
recent RCTs conducted in the United States10,24,30 are more
similar to those observed in Europe, which suggests that our
results may be generalisable to current U.S. practice.
4.1. Strengths and limitations
To the best of our knowledge, this is the first randomised
controlled study to examine the clinical utility and diagnostic value
of SCS screening trials. Our study was independently funded and
conducted with oversight from a registered clinical trials unit. To
date, only 2 other RCTs assessing the impact of SCS have
reported industry-independent funding, and both recruited
considerably fewer patients from a smaller number of centres.9,25
The recruitment from 3 United Kingdom centres makes our
findings generalisable to United Kingdom and possibly European
practice. In addition, the use of pragmatic inclusion criteria that
closely mirror the United Kingdom NICE guidance as well as the
use of devices from all major SCSmanufacturers ensures that our
findings portray the real-world impact of SCS.
We sought to eliminate participant expectation bias through
use of a carefully balanced message to participants around the
benefits/risks of screening trials. In addition, we blinded
observers and analysts to group allocation.
All devices were programmed by pain clinic nurses within the
routine clinical setting and at routine clinical review timepoints
selected to limit participant burden. Only 2 individual pro-
gramming appointments occurred outside the study visits.
Finally, this is the first RCT to examine the role of SCS as a
generic intervention rather than a device-specific outcome.
Spinal cord stimulation devices were programmed to paresthe-
sia, 10 Khz, and burst modes of stimulation. Although the study
was not powered to detect statistically significant differences
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between the 3 programming modalities, we were unable to
observe clinically relevant differences.
Our study has some limitations. Due to the nature of the study
interventions, we were unable to blind participants or physicians.
As this was a pragmatic trial reflecting United Kingdom clinical
practice, we did not test for neuropathic pain because NICE
guidance does not dictate the use of a test other than clinical
diagnosis. Inclusion of a population based on IASP criteria or any
specific diagnostic neuropathic pain test may not represent the
population treated with SCS in United Kingdom clinical practice
thus limiting our ability to influence United Kingdom practice and
commissioning. Our findings specifically on the diagnostic utility
of the screening trial are compromised by the small number of
subjects failing a screening trial as well as the loss to follow-up of
3/5 patients with a failed screening trial. Finally, our findings on the
diagnostic utility and cost-effectiveness of screening trials may
not be applicable to other healthcare settings (such as United
States) where trial success rates are typically much lower than
seen in this study and other European settings.22,31
4.2. Practice implications
Our findings have substantial potential implications for the future
practice. Over the past 50 years, screening trials have been used
to determine the suitability of patients for permanent SCS
implantation. Indeed, many healthcare systems (eg, United
Kingdom, Belgium) mandate that patients with chronic pain
cannot be provided with a SCS system without first demonstra-
tion of positive screening trial. However, our results challenge this
dogma. Although more evidence needs to be collected on the
utility of SCS screening trials in different healthcare settings and
clinical patient populations, our findings indicate that SCS
screening trials should certainly no longer bemandatory. Instead,
future patient selection for SCS should be based on careful
multidisciplinary clinical assessment of their suitability that
includes a psychological evaluation by an experienced psychol-
ogist, rather than the application of a simple screening trial. Since
completion of the TRIAL-STIM study, a European consensus and
educational tool on the appropriate referral and selection of
patients with chronic pain for SCS has been published.40 The tool
supports reliance on multidisciplinary selection rather than trial
periods as the dominant criterion to predict successful long-term
SCS outcome.
The COVID-19 pandemic raises additional concerns into risks
associated with potentially avoidable surgical procedures as is
the case of a 2-stage surgery due to a screening trial of SCS. High
rates of mortality (20.5%) and intensive care unit admission
(44.1%) have been reported in patients who had elective
surgeries during the incubation period of COVID-19.27 Screening
trials are likely to be undesirable from the perspective of both
caregiver and patient in this new era after COVID-19.
In conclusion, the results of this RCT indicate that although
there may be some diagnostic utility of a screening TG for SCS
implantation, compared to a no screen strategy, there is no
patient outcome benefit. Furthermore, we found that a screening
TG incurs more costs in a United Kingdom NHS setting and is
unlikely to represent value for money.
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